Free Trial

Chimerix (CMRX) FDA Events

Chimerix logo
$8.54 0.00 (0.00%)
As of 04/21/2025
FDA Events for Chimerix (CMRX)

This section highlights FDA-related milestones and regulatory updates for drugs developed by Chimerix (CMRX). Over the past two years, Chimerix has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as dordaviprone. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

dordaviprone - FDA Regulatory Timeline and Events

dordaviprone is a drug developed by Chimerix for the following indication: treatment for recurrent H3 K27M-mutant diffuse glioma. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Chimerix FDA Events - Frequently Asked Questions

As of now, Chimerix (CMRX) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Chimerix (CMRX) has reported FDA regulatory activity for dordaviprone.

The most recent FDA-related event for Chimerix occurred on February 18, 2025, involving dordaviprone. The update was categorized as "FDA Accepted," with the company reporting: "Chimerix announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma."

Currently, Chimerix has one therapy (dordaviprone) targeting the following condition: treatment for recurrent H3 K27M-mutant diffuse glioma.

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:CMRX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners